First PIP recommendation to broaden Cancidas' EU indication
This article was originally published in Scrip
Executive Summary
Merck & Co's antifungal Cancidas (caspofungin) is set to have its approved indications expanded in the EU to include paediatric patients following a positive opinion from the EU's CHMP– the first to be made based on clinical trial data generated in accordance with an agreed paediatric investigation plan (PIP). The echinocandin is currently approved in Europe for the treatment of several severe fungal infections, and is now approved for use in these infections in children aged 12 months to 17 years. The indications are: treatment of invasive candidiasis; treatment of invasive aspergillosis in patients refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B, and/or itraconazole; and empirical therapy for presumed fungal infections in febrile neutropenic patients. PIPs are agreed in advance by the European Medicines Agency Paediatric Committeeand are legally binding for companies developing medicinal products for use in the EU.
You may also be interested in...
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.